Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
- A Federal Coronavirus Vaccine Contract Released At Last, But Redactions Obscure Terms
- FDA Panel To Lay Regulatory Groundwork For COVID-19 Vaccine
- A Look At Why Johnson & Johnson Paused Coronavirus Vaccine Trial
- Call For Administration's COVID-19 Vaccine Contracts To Be Disclosed
- FDA Releases Long-Awaited COVID-19 Vaccine Guidance
- How Operation Warp Speed's Big Vaccine Contracts Could Stay Secret
- What To Know About Those $200 Drug Cards President Trump Promised
- CDC Releases Plan For Coronavirus Vaccine Distribution
- 9 Companies Pledge Not To Submit Coronavirus Vaccine To FDA Until It's Proved Safe
- How Feds Decide On Remdesivir Shipments To States Remains Mysterious
- Prices For COVID-19 Vaccines Are Starting To Come Into Focus
- U.S. To Get 100 Million Doses of Pfizer Coronavirus Vaccine In $1.95 Billion Deal